The company, a majority-owned affiliate of Ionis Pharmaceuticals, announced Sept. 23 the departures of CEO Paula Soteropoulos, President Sarah Boyce and COO Jeff Goldberg, effective immediately.
Danueb McDevitt, PhD, the chief business officer of Ionis was named interim CEO. The company didn’t announce interim replacements for the president or COO.
The leadership shakeup comes a year after the company launched its first FDA-approved drug, Tegsedi, a treatment for a rare disease called hereditary transthyretin amyloidosis, according to STAT.
More articles on pharmacy:
Carcinogen concerns prompt Sandoz to halt global distribution of heartburn drug
DEA raids some West Coast Kaiser Permanente pharmacies
California biotech files for bankruptcy
